These results confirm that high IGF2BP3lac levels correlate with poor therapeutic responses to lenvatinib and that targeting IGF2BP3 can effectively restore lenvatinib sensitivity in HCC. This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.